MedTrace Logo

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

NCT03558165 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2022-05-17

No results posted yet for this study

Summary

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, to profile stage IV lung cancer patients.

Conditions

  • Lung Cancer Stage IV

Interventions

DIAGNOSTIC_TEST

Oncomine Comprehensive Assay

Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay

Sponsors & Collaborators

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • The Princess Margaret Cancer Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-08-20
Completion
2022-02-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03558165 on ClinicalTrials.gov